PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification

Summary

In this Project, we will use therapeutic target -focused (TTF) profiling, genome-wide mRNA profiling and assessments of tumor phosphopeptides and DNA that are shed into the blood stream to define how various molecular factors alone and in combination relate to resistance to therapy, to prognosis, and to metastatic patterns at relapse. We will examine how the presence of factors that drive cell growth, antagonize apoptosis, or confer resistance in other ways may counter the effect of systemic therapies and/or promote rapid tumor recurrence. In this way, we will identify new, previously unappreciated potential therapeutic targets while also identifying which targets are most likely to increase resistance to therapy and worsen prognosis.

Conditions

• Lung Cancer
• Cancer of Thorax

Interventions

OTHER

Group Specific Aim 1

600 cases: two normal and two tumor formalin-fixed tissue samples

OTHER

Group Specific Aim 2

600 cases: two normal and two tumor formalin-fixed tissue samples.

OTHER

Group Specific Aim 3

600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples

OTHER

Group Specific Aim 4

600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples

OTHER

Group Specific Aim 5

600 cases; two normal and two tumor formalin-fixed tissue samples

OTHER

Group Specific Aim 6

210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.

Sponsors & Collaborators

• United States Department of Defense

  collaborator FED

• National Institutes of Health (NIH)

  collaborator NIH

• National Cancer Institute (NCI)

  collaborator NIH

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Luisa M Solis Soto, MD · M.D. Anderson Cancer Center

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-04-25

Primary Completion

2025-12-31

Completion

2025-12-31

Countries

• United States

Study Locations